These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31119864)

  • 1. Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.
    Singh V; Tripathi A; Dutta R
    Proteomics; 2019 Aug; 19(16):e1800335. PubMed ID: 31119864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics in Multiple Sclerosis: The Perspective of the Clinician.
    Sandi D; Kokas Z; Biernacki T; Bencsik K; Klivényi P; Vécsei L
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers.
    Sen MK; Almuslehi MSM; Shortland PJ; Mahns DA; Coorssen JR
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum proteomics in multiple sclerosis disease progression.
    Tremlett H; Dai DL; Hollander Z; Kapanen A; Aziz T; Wilson-McManus JE; Tebbutt SJ; Borchers CH; Oger J; Cohen Freue GV
    J Proteomics; 2015 Apr; 118():2-11. PubMed ID: 25753122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid proteomics in multiple sclerosis.
    Kroksveen AC; Opsahl JA; Guldbrandsen A; Myhr KM; Oveland E; Torkildsen Ø; Berven FS
    Biochim Biophys Acta; 2015 Jul; 1854(7):746-56. PubMed ID: 25526888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.
    Dagley LF; Emili A; Purcell AW
    Proteomics Clin Appl; 2013 Jan; 7(1-2):91-108. PubMed ID: 23112123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
    Fawaz CN; Makki IS; Kazan JM; Gebara NY; Andary FS; Itani MM; El-Sayyed M; Zeidan A; Quartarone A; Darwish H; Mondello S
    Expert Rev Proteomics; 2015; 12(6):637-50. PubMed ID: 26479122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics in multiple sclerosis.
    Bhargava P; Calabresi PA
    Mult Scler; 2016 Apr; 22(4):451-60. PubMed ID: 26754801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis.
    Martin R; Sospedra M; Rosito M; Engelhardt B
    Eur J Immunol; 2016 Sep; 46(9):2078-90. PubMed ID: 27467894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.
    Chase Huizar C; Raphael I; Forsthuber TG
    Cell Immunol; 2020 Dec; 358():104219. PubMed ID: 33039896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Top-down proteomic profiling of human saliva in multiple sclerosis patients.
    Manconi B; Liori B; Cabras T; Vincenzoni F; Iavarone F; Lorefice L; Cocco E; Castagnola M; Messana I; Olianas A
    J Proteomics; 2018 Sep; 187():212-222. PubMed ID: 30086402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics technologies for biomarker discovery in multiple sclerosis.
    Singh V; Hintzen RQ; Luider TM; Stoop MP
    J Neuroimmunol; 2012 Jul; 248(1-2):40-7. PubMed ID: 22129845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodegeneration in multiple sclerosis.
    Mey GM; Mahajan KR; DeSilva TM
    WIREs Mech Dis; 2023 Jan; 15(1):e1583. PubMed ID: 35948371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review.
    Gul M; Jafari AA; Shah M; Mirmoeeni S; Haider SU; Moinuddin S; Chaudhry A
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometry-based proteomic techniques to identify cerebrospinal fluid biomarkers for diagnosing suspected central nervous system infections. A systematic review.
    Bharucha T; Gangadharan B; Kumar A; de Lamballerie X; Newton PN; Winterberg M; Dubot-Pérès A; Zitzmann N
    J Infect; 2019 Nov; 79(5):407-418. PubMed ID: 31404562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic signatures of neuroinflammation in Alzheimer's disease, multiple sclerosis and ischemic stroke.
    Thygesen C; Larsen MR; Finsen B
    Expert Rev Proteomics; 2019 Jul; 16(7):601-611. PubMed ID: 31220951
    [No Abstract]   [Full Text] [Related]  

  • 17. How can proteomics elucidate the complexity of multiple sclerosis?
    Farias AS; Santos LM
    Proteomics Clin Appl; 2015 Oct; 9(9-10):844-7. PubMed ID: 25980360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes.
    Avsar T; Durası İM; Uygunoğlu U; Tütüncü M; Demirci NO; Saip S; Sezerman OU; Siva A; Tahir Turanlı E
    PLoS One; 2015; 10(5):e0122045. PubMed ID: 25942430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.
    Kroksveen AC; Jaffe JD; Aasebø E; Barsnes H; Bjørlykke Y; Franciotta D; Keshishian H; Myhr KM; Opsahl JA; van Pesch V; Teunissen CE; Torkildsen Ø; Ulvik RJ; Vethe H; Carr SA; Berven FS
    Proteomics; 2015 Oct; 15(19):3361-9. PubMed ID: 26152395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis.
    Borràs E; Cantó E; Choi M; Maria Villar L; Álvarez-Cermeño JC; Chiva C; Montalban X; Vitek O; Comabella M; Sabidó E
    Mol Cell Proteomics; 2016 Jan; 15(1):318-28. PubMed ID: 26552840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.